Mycobind is a plant-derived biotechnology platform that leverages the natural binding properties of bioactive plant compounds to neutralise harmful toxins and pathogens — delivering protection grounded in rigorous scientific evidence.
Bioactive compounds extracted from rigorously screened plant species with proven binding affinity.
Precision formulation and characterisation guided by MIC screening and evidence-based research.
Targeted neutralisation of harmful compounds — addressing the challenge at the molecular level.
Mycobind is a plant-based biotechnology product developed to address the persistent challenge of [mycotoxin contamination / harmful pathogen exposure — edit to your specific problem]. Drawing on an extensive library of plant infusions, Mycobind identifies and harnesses bioactive compounds with potent binding and neutralising properties.
Underpinned by rigorous laboratory research — including minimum inhibitory concentration (MIC) screening across clinically relevant strains — Mycobind delivers a credible, evidence-based alternative to existing solutions.
Our approach sits at the intersection of traditional plant science and modern biotechnology, offering a naturally sourced, scalable, and commercially viable pathway to protection.
All data from triplicate laboratory readings. Full results available in the research portal.
View All Research Findings[Describe the problem here — e.g. mycotoxin contamination in food/feed, antimicrobial resistance, pathogen exposure in a specific industry. Explain the scale of the challenge, why existing solutions are insufficient, and who bears the burden of the problem.]
[Describe this aspect of the problem — scale, impact, current gaps in solutions.]
[Describe economic, health or environmental impact of the problem in this area.]
[Describe why current solutions fall short and what gap Mycobind fills.]
Mycobind's action is grounded in the natural binding properties of specific plant bioactive compounds, validated through systematic laboratory screening.
[Describe how the plant compounds are extracted or prepared for the binding function.]
[Describe how the bioactive compounds bind to the target toxin or pathogen.]
[Describe what happens after binding — neutralisation, elimination, or safe passage.]
[Describe the end result and how this translates to a product or commercial application.]
Mycobind is currently at [development stage]. Below is an overview of our progress and the pathway to full commercialisation.
Initial plant species screening, MIC determination, and compound identification — completed.
[Description of this development stage — e.g. preclinical validation, formulation development]
[Description — e.g. regulatory submission, pilot production, clinical trials]
[Licensing, manufacturing partnerships, and routes to market — target timeline]
We welcome enquiries from industry partners, investors, and research collaborators. Get in touch to discuss licensing arrangements or co-development opportunities.
